Navigation Links
Jury Returns Verdict in VNUS' Patent Infringement Lawsuit With Total Vein Systems and biolitec Finding Some Patent Claims Invalid and Some Infringed
Date:12/9/2010

HOUSTON, Dec. 9, 2010 /PRNewswire/ -- After a lengthy seven-week trial in VNUS' lawsuit against Total Vein Solutions, LLC d/b/a Total Vein Systems ("TVS") and biolitec, Inc. ("biolitec"), a federal jury in San Francisco has returned a verdict finding invalidity of many of the claims of VNUS' patents, and infringement of others.  

"TVS agrees with the jury's findings that certain claims in VNUS' '084, '803 and '355 patents were invalid as "obvious," but is displeased with the jury's verdict of infringement and damages."  Tyri Schiek, President and co-owner of TVS commented, "It has always been and remains our position that TVS does not infringe anyone's patents by selling unpatented, standard medical supplies.  We believe all of the VNUS method patents are invalid."   David Centanni, co-owner and CEO of TVS, added that "we disagree with the jury's conclusion on infringement and think the jury's findings on damages were grossly inflated.  TVS will continue business as usual and is confident that those findings of the jury that were in error will be overturned, either by the trial court or at the appellate level.  Total Vein remains dedicated to providing the highest quality medical products to physicians and clinics at fair and equitable prices."

VNUS sued TVS, among others, in 2008, for indirect patent infringement, by way of contributory and induced infringement, relating to TVS' sales of laser fibers, laser consoles, introducer kits and procedure packs.  The patents at issue do not cover a particular product or device, but instead claim a method of performing endovenous ablation with vein compression.  

TVS has steadfastly denied that its sales of unpatented products amount to infringing conduct.  TVS also noted that the patents do not adequately enable doctors to perform the methods using laser or microwave energy modalities without "undue experimentation," despite claiming such.  Moreover, TVS and biolitec argued that a variety of publications show that the same endovenous ablation methods existed long before, and that VNUS' claimed procedure is merely an obvious variant of such earlier described methods.  

TVS expects that it will file all necessary motions in the trial court to overturn the portions of the jury's decision that were in error, and will appeal where necessary.  Contact: David Centanni, CEO and co-ownerTyri Schiek, President and co-owner888 868-8346
'/>"/>

SOURCE Total Vein Solutions, LLC d/b/a Total Vein Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Donors Needed as School, Fall Season Returns
2. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
3. Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
4. Molecular Devices Returns to Life Sciences Marketplace
5. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
6. Segal McCambridge Singer & Mahoney, Ltd. and Greenberg Traurig, LLP Obtain Three Defense Verdicts for I-Flow in Oregon Infusion Pump Cases
7. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
8. Maryland Woman Thankful for Wyeth Verdicts
9. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
10. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
11. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):